The Phase 3 RISE UP trial has marked a significant step forward in addressing sickle cell disease (SCD). @Agios Pharmaceuticals has completed enrollment for this pivotal study. The trial is assessing the potential of mitapivat, an experimental oral drug, to effectively treat SCD in individuals aged 16 and older. Over 200 participants are taking part in this global study, which will evaluate key factors such as hemoglobin response and the frequency of sickle cell pain crises over a year-long period.

Agios is optimistic about the study, expecting to share topline results in late 2025. Mitapivat’s approach involves enhancing the energy mechanisms within red blood cells, aiming to reduce the tendency of sickling, a critical challenge in SCD management. Dr. @Sarah Gheuens, the Chief Medical Officer at Agios, thanked everyone involved for their indispensable contributions to the trial’s progress.

At OxyDial, we’re inspired by Agios’s dedication to combating SCD and advancing patient care in rare blood disorders. The completion of this trial enrollment underscores the crucial role of continued research and collaboration in improving the lives of those living with complex conditions.

Read more: https://www.investing.com/news/company-news/agios-completes-enrollment-for-sickle-cell-disease-trial-93CH-3677225

#AgiosPharma #SickleCellDisease #RISEUPTrial #Mitapivat #HematologyResearch #RareDiseases #ClinicalTrials